DDR1 and non-small cell lung carcinoma: As this panel was historical, many notable prognostic biomarkers that would be considered useful today, such as FGFR1 or FGFR3 amplification, RET, MET, DDR, KRAS, BRAF and PIK3CA, were not included for the selection of targeted therapy in the NSCLC cohort.